These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33116409)

  • 1. Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
    Nakamura T; Asanuma K; Hagi T; Sudo A
    Drug Des Devel Ther; 2020; 14():4215-4220. PubMed ID: 33116409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
    Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
    Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
    Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
    BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
    Karch A; Koch A; Grünwald V
    Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin.
    Tsuchihashi K; Kusaba H; Yoshihiro T; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Imajima T; Shinohara Y; Ito M; Yamaga S; Tanoue K; Arimizu K; Ohmura H; Hanamura F; Yamaguchi K; Isobe T; Ariyama H; Nakashima Y; Akashi K; Baba E
    Sci Rep; 2020 Dec; 10(1):20896. PubMed ID: 33262403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.
    Mochizuki T; Ikegami M; Akiyama T
    Cancer Sci; 2024 Feb; 115(2):575-588. PubMed ID: 38115234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
    Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
    Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
    Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
    Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
    Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
    Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group.
    Giani C; Denu RA; Ljevar S; Gronchi A; Napolitano A; Rosenbaum E; Salawu A; Bajpai J; Connolly EA; Lee ATJ; Trent JC; Koseła-Paterczyk H; Chia-Chen Li Z; Ogura K; Palmerini E; Baldi GG; Brunello A; Campos F; Cicala CM; Maki RG; Wagner AJ; Andelkovic V; Loong HH; Wong DD; Jones RL; Tap WD; Taverna SM; Lazar AJ; Demicco EG; Hong A; Bovee JVMG; Dei Tos AP; Fletcher CDM; Baumhoer D; Sbaraglia M; Schaefer IM; Miceli R; Stacchiotti S
    ESMO Open; 2024 Sep; 9(9):103689. PubMed ID: 39265219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
    Van Tine BA; Trent JC
    Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
    Sharma S; Takyar S; Manson SC; Powell S; Penel N
    BMC Cancer; 2013 Aug; 13():385. PubMed ID: 23937858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
    Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S
    Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
    Touati N; Schöffski P; Litière S; Judson I; Sleijfer S; van der Graaf WT; Italiano A; Isambert N; Gil T; Blay JY; Stark D; Brodowicz T; Marréaud S; Gronchi A
    Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):448-454. PubMed ID: 29550245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
    Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
    Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS
    Oncology; 2019; 96(2):59-69. PubMed ID: 30336470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin.
    Simetić L; Blažičević K; Ladenhauser T; Golčić M; Majnarić T; Herceg D
    Anticancer Drugs; 2021 Nov; 32(10):1058-1066. PubMed ID: 34232944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival.
    Garbay D; Maki RG; Blay JY; Isambert N; Piperno Neumann S; Blay C; Zanardi E; Boudou-Rouquette P; Bozec L; Duffaud F; Bertucci F; Italiano A
    Ann Oncol; 2013 Jul; 24(7):1924-1930. PubMed ID: 23493135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
    Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
    Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.